Kelli Gross, MD
Urology · Scottsdale, AZNPI 1154731685
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (28.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Coloplast at 31.3% of the total. 2025 is the largest year on record at $8,448, 3.2 times the $2,662 reported in 2019.
Across 164 payments — averaging $128.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$7K
- Cook Incorporated$6K
- Boston Scientific$4K
- Endo Pharmaceuticals Inc.$3K
- Cook Medical LLC$1K
- Pfizer$100
- plus $151 from 2 others
What the payments were for
- Consulting fees$3,12515%
- Speaking & faculty fees$6,06029%
- Travel & lodging$4,93523%
- Food & beverage$6,10429%
- Education$8904%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 102 | $6,602 |
| Cook Incorporated | 1 | $6,060 |
| Boston Scientific | 49 | $3,545 |
| Endo Pharmaceuticals Inc. | 2 | $3,180 |
| Cook Medical LLC | 7 | $1,477 |
| Pfizer | 1 | $100 |
| Acerus Pharmaceuticals Corporation | 1 | $76 |
| Bayer | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LITHO 150$7,197
- XIAFLEX$3,125
- TITAN$2,886
- AMS$1,510
- PENILE & TESTICULAR RECONSTRUCTN$687
- GENERAL ERECTILE DYSFUNCTION$137
- AMS 700$136
- AMS 700 CXR RTE KIT$134
- REZUM$121
- TACTRA$111
- S~Curve$105
- XTANDI$100
How this compares
$21,114 in reported general payments places this provider in the 85th percentile of 269 urology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 27 | $11,565 |
| Testosterone Cypionate | 24 | $1,037 |
| Finasteride | 48 | $665 |
| Tamsulosin Hcl | 33 | $554 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $349 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $28 |
Paid to pharmacies, not to this prescriber.
Other urology in Scottsdale
- Michael ZellScottsdale$64K
- Thayne LarsonScottsdale$48K
- Jackson CaboScottsdale$36K
- Mark TysonScottsdale$34K
- Anojan NavaratnamScottsdale$30K
- Bernard GburekScottsdale$27K
- Matthew SteinwayScottsdale$23K
- James DaitchScottsdale$16K
- Daniel FrendlScottsdale$15K
- Mitchell HumphreysPhoenix$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.